<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992328</url>
  </required_header>
  <id_info>
    <org_study_id>MED-CT4-12-405</org_study_id>
    <nct_id>NCT01992328</nct_id>
  </id_info>
  <brief_title>IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency</brief_title>
  <acronym>IVIG</acronym>
  <official_title>IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunoglobulin G deficiency subtypes in patients with asthma six months once a month
      intravenous immunoglobulin (400mg/kg/4weeks) infection in treatment-related effect on
      reducing the frequency of asthma exacerbations appreciate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients Registration

      •It is required to ensure that the patients meet the inclusion criteria for this clinical
      trial, are free from any items of exclusion criteria, are explained about the participation
      in the clinical trial along with the informed consent forms.

      Procedure

      •six months once a month intravenous immunoglobulin (400mg/kg/4weeks)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infection rate</measure>
    <time_frame>6months</time_frame>
    <description>6 months after treatment compared to before treatment 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lung funtion</measure>
    <time_frame>6 months</time_frame>
    <description>- Lung function (FEV1) compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>steroid</measure>
    <time_frame>6 months af</time_frame>
    <description>- Systemic steroid dose and the number of uses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antibiotic</measure>
    <time_frame>6months</time_frame>
    <description>- The frequency and duration of antibiotic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asthma syptoms</measure>
    <time_frame>6months</time_frame>
    <description>- The frequency of asthma exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>6months</time_frame>
    <description>- Asthma Quality of Life (AQOL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnair</measure>
    <time_frame>6months</time_frame>
    <description>- Asthma control score (K-ACT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG subclass</measure>
    <time_frame>6months</time_frame>
    <description>- Before and after treatment serum IgG subclass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>6months</time_frame>
    <description>- Cytokines serum levels before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>6months</time_frame>
    <description>- The frequency of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Immune Globulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunoglobulin G Deficiency Associated with persistent asthma subtypes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune Globulin</intervention_name>
    <description>6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)</description>
    <arm_group_label>Immune Globulin</arm_group_label>
    <other_name>Immunoglobulin G Deficiency</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient from over 16 years to under 75 years

          -  Patients diagnosed with asthma over six months ago

          -  immunoglobulin G subtypes who were diagnosed with immune deficiency

          -  more than 2 years Upper and lower respiratory tract infections

             , and asthma exacerbations in this regard.

          -  ① calculated creatinine clearance ≧ 50ml/min

               -  ALT and AST &lt;x 3 times the upper limit of normal

                    -  ALP &lt;x 3 times the upper limit of normal

                         -  total bilirubin &lt;x 1.5 times the upper limit of normal

        Exclusion Criteria:

          -  within six months of the onset of the experiment who received immunoglobulin therapy

          -  immune globulin for those with a history of hypersensitivity reactions

          -  six months ago, another clinical trial participants.

          -  Systemic steroids and immunomodulators, such as asthma control that may affect the
             resources required drug administration.

          -  pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hae-sim park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of medicine, Ajou University School of Medicine</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Hae-Sim Park</investigator_full_name>
    <investigator_title>Professor, Department of medicine, Ajou University School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Immunoglobulin G Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>IgG Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

